CD274 and neoplasm: While many molecular drivers and gene mutations, such as PDL-1 positivity, tumor-infiltrating lymphocyte (TIL) and germline BRCA carriage, do not appear to derive substantial benefit from anthracyclines, it remains unclear which specific tumor features and breast cancer populations would benefit the most from TC over anthracycline-taxane chemotherapy [36,37,38].